AbbVie | ABBV - Net Income



AbbVie reported $938M in Net Income for its fiscal quarter ending in June of 2025.


Net Income Change Date
AbbVie USD 938M 348M Jun/2025
Abbott USD 1.78B 454M Jun/2025
ALKERMES USD 87.1M 64.63M Jun/2025
Amgen USD 1.43B 298M Jun/2025
AstraZeneca USD 2.45B 466M Jun/2025
Biogen USD 634.8M 394.3M Jun/2025
BioMarin Pharmaceutical USD 240.53M 54.85M Jun/2025
Bristol-Myers Squibb USD 1.31B 1.15B Jun/2025
Eisai JPY 14.47B 13.52B Jun/2025
Eli Lilly USD 5.66B 2.9B Jun/2025
Gilead Sciences USD 1.96B 645M Jun/2025
GlaxoSmithKline GBP 1.44B 181M Jun/2025
J&J USD 5.54B 5.46B Jun/2025
Medtronic USD 1.04B 17M Jul/2025
Merck USD 4.43B 652M Jun/2025
Neurocrine Biosciences USD 107.5M 99.6M Jun/2025
Novartis USD 4.02B 418M Jun/2025
Pacira USD -4847000 9.66M Jun/2025
Perrigo USD -8400000 2M Jun/2025
Pfizer USD 2.91B 58M Jun/2025
Regeneron Pharmaceuticals USD 1.39B 582.9M Jun/2025
Roche Holding CHF 1.01B 2.12B Dec/2024
Sanofi EUR 3.94B 2.07B Jun/2025
UCB EUR 857M 649M Dec/2024
Ultragenyx Pharmaceutical USD -114951000 36.13M Jun/2025
United Therapeutics USD 309.5M 12.7M Jun/2025
Vertex Pharmaceuticals USD 1.03B 386.6M Jun/2025
Zoetis USD 718M 87M Jun/2025